Journey Medical Corp

Journey Medical Corp

DERM · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

4.33USD-0.06 (-1.37%)

Price History

Full chart

Market Stats

Previous Close4.39
Open4.20
Day Range4.00 – 4.53
52-Week Range4.31 – 9.56
Volume387.16K
Market Cap178.38M
P/E (TTM)0.00
Forward P/E10.21
EPS-0.21
Dividend Yield0.00%
Beta1.10
50-Day Avg7.00
200-Day Avg6.91

About

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Claude Maraoui
  • Employees58
  • Headquarters9237 East Via de Ventura Blvd., Scottsdale, AZ, United States, 85258, USA
  • Websitehttps://journeymedicalcorp.com

Leadership

  • Dr. Lindsay Allan Rosenwald M.D.Executive Chairman · b. 1955
  • Mr. Claude MaraouiFounder, President, CEO & Director · b. 1967
  • Mr. Joseph M. BeneschCFO & Corporate Controller · b. 1967
  • Mr. Ramsey AlloushCOO, General Counsel & Company Secretary · b. 1986
  • Mr. Brian ProutExecutive Director of Marketing
  • Mr. Robert NevinChief Commercial Officer · b. 1969
  • Jaclyn JaffeSenior Director of Corporate Operations
  • Mr. Louis DonatiDirector of Market Access

Financials

Income Statement

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue7.30M7.30M22.59M4.54M42.34M34.92M44.53M63.13M73.67M79.18M56.13M61.86M
Growth (%)-0.00%+209.38%-79.89%+832.37%-17.52%+27.52%+41.78%+16.69%+7.48%-29.11%+10.20%
Cost of Revenue----1.18M10.53M14.59M32.08M30.77M26.66M20.88M25.18M
Gross Profit7.30M7.30M22.59M4.54M41.16M24.39M29.94M31.05M42.89M52.52M35.26M36.68M
Gross Margin100.00%100.00%100.00%100.00%97.22%69.84%67.23%49.18%58.23%66.33%62.81%59.29%
Operating Expense39.00M87.07M113.21M304.87M255.15M19.13M22.09M65.93M70.41M54.59M48.93M44.85M
Operating Income-31.70M-79.77M-90.62M-300.33M-213.98M5.26M7.85M-34.88M-27.52M-2.07M-13.68M-8.17M
Operating Margin-434.22%-1092.74%-401.26%-6613.65%-505.40%15.06%17.63%-55.25%-37.35%-2.62%-24.36%-13.21%
EBITDA-31.64M-78.80M-87.42M-294.78M-205.54M6.44M9.28M-32.77M-23.18M1.92M-8.40M-3.33M
EBITDA Margin-433.48%-1079.48%-387.08%-6491.57%-485.46%18.44%20.83%-51.90%-31.47%2.43%-14.96%-5.38%
Net Income-31.88M-78.40M-89.08M-303.26M-221.54M3.63M5.28M-43.99M-29.63M-3.85M-14.67M-11.43M
Net Income Margin-436.64%-1073.96%-394.44%-6678.29%-523.25%10.38%11.86%-69.68%-40.22%-4.87%-26.14%-18.48%
R&D30.71M66.83M83.17M104.41M80.55M-016.56M10.94M7.54M9.86M480.00K
R&D as % of Total Revenue420.68%915.49%368.24%2299.25%190.24%-0.00%26.23%14.85%9.52%17.56%0.78%
Interest Expense153.00K147.00K1.54M8.14M15.64M255.00K698.00K7.03M2.02M1.70M2.70M3.70M
Interest Expense % of Total Revenue2.10%2.01%6.82%179.26%36.94%0.73%1.57%11.14%2.74%2.14%4.81%5.98%

Balance Sheet

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets178.22M221.93M312.60M560.79M344.32M33.86M51.91M97.28M105.16M76.85M80.24M94.59M
Total Liabilities24.64M36.46M65.23M411.14M353.36M31.11M41.61M55.24M88.18M56.50M60.17M62.74M
Total Equity153.58M185.47M247.37M149.65M-9.04M2.75M10.29M42.04M16.98M20.35M20.07M31.85M
Cash55.36M107.24M41.79M295.92M104.98M4.80M8.25M49.08M32.00M27.44M20.30M24.09M
Total Debt1.94M--279.39M313.79M5.30M9.92M9.05M22.96M17.73M25.70M25.40M
Net Debt-53.42M-107.24M-41.79M-16.53M208.81M502.00K1.68M-40.03M-9.04M-9.71M5.40M1.31M

Cash Flow

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-31.40M-48.44M-74.11M-103.96M-213.10M9.02M5.13M-2.18M-13.53M5.24M-9.13M-12.44M
Investing Cash Flow-109.48M-2.60M-130.29M-104.43M-13.23M-2.40M-1.20M-10.00M-20.00M-5.00M-15.00M-
Financing Cash Flow174.10M102.93M138.95M462.52M35.38M-3.55M-487.00K53.02M16.46M-4.80M16.99M16.23M
Capital Expenditure156.00K202.00K753.00K278.00K616.00K2.40M1.20M10.00M20.00M5.00M15.00M0
Free Cash Flow-31.56M-48.64M-74.86M-104.24M-213.71M6.62M3.93M-12.18M-33.53M240.00K-24.13M-12.44M
Dividends Paid-------1.55M371.00K---
FCF to OCF100.50%100.42%101.02%100.27%100.29%73.39%76.62%558.51%247.78%4.58%264.35%100.00%
Dividend Paid to FCF--------12.72%-1.11%---

Earnings

Report DateNov 12, 2014Mar 25, 2015May 12, 2015Aug 13, 2015Nov 10, 2015Mar 3, 2016May 10, 2016Aug 8, 2016Nov 7, 2016Feb 28, 2017May 8, 2017Aug 7, 2017Nov 6, 2017Feb 22, 2018May 3, 2018Aug 6, 2018Nov 7, 2018Feb 26, 2019May 7, 2019Aug 7, 2019Nov 5, 2019Sep 1, 2021Dec 10, 2021Mar 23, 2022May 10, 2022Aug 9, 2022Nov 10, 2022Mar 29, 2023May 22, 2023Aug 8, 2023Nov 7, 2023Mar 21, 2024May 13, 2024Aug 12, 2024Nov 12, 2024Mar 26, 2025May 14, 2025Aug 12, 2025Nov 12, 2025Mar 19, 2026May 13, 2026Aug 12, 2026Nov 11, 2026
EPS Estimate-0.93-0.60-0.65-0.75-0.77-0.95-0.94-0.86-0.72-0.80-0.89-0.89-1.12-1.22-1.36-0.51-1.63-1.91-1.62-0.95-1.30-1.30-0.87-0.41-0.31-0.26-0.40-0.47-0.45-0.33-0.15-0.08-0.23-0.14-0.15-0.17-0.24-0.10-0.04-0.04-0.09-0.010.01
EPS Actual-8.67-0.29-0.57-0.69-0.58-1.04-0.95-0.89-0.72-0.21-0.79-0.93-4.30-1.34-1.42-0.57-1.58-1.70-1.49-0.33-1.06-0.72-1.16-1.64-0.08-0.43-0.57-0.60-0.57-0.460.80-0.12-0.53-0.17-0.120.10-0.18-0.16-0.09-0.04-0.08-0.01-
Surprise-832.26%51.67%12.31%8.00%24.68%-9.47%-1.06%-3.49%0.00%73.75%11.24%-4.49%-283.93%-9.84%-4.41%-11.76%3.07%10.99%8.02%65.26%18.46%44.62%-33.33%-300.00%74.19%-65.38%-42.50%-27.66%-26.67%-39.39%633.33%-50.00%-130.43%-21.43%20.00%157.97%25.00%-60.00%-125.00%0.00%11.11%0.00%-
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap178.38M
Enterprise Value183.64M
Trailing P/E0.00
Forward P/E10.21
Price / Sales2.62
Price / Book6.37
EPS-0.21
Book Value1.16
Revenue (TTM)68.18M
Gross Profit (TTM)44.63M
EBITDA1.22M
Profit Margin-8.95%
Operating Margin2.46%
Return on Equity-23.77%
Return on Assets-2.10%
Shares Outstanding22.22M
Shares Float15.59M
Beta1.10
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 4 analystsTarget 13.75
  • Strong Buy
    3
  • Buy
    1

Ownership Breakdown

Institutions
48.63%
Insiders
31.75%
Retail / Other
19.62%

Top Institutional Holders

  • Wasatch Advisors LP
    2.86M10.13%
  • TANG CAPITAL MANAGEMENT LLC
    1.61M5.70%
  • Vanguard Capital Management, LLC
    1.08M3.83%
  • BlackRock Inc
    972.86K3.45%
  • Punch & Associates Inv Mgmt Inc
    536.00K1.90%
  • Pale Fire Capital SE
    528.58K1.87%
  • J. Goldman & Co LP
    500.19K1.77%
  • Geode Capital Management, LLC
    463.20K1.64%
  • UBS Group AG
    390.14K1.38%
  • Opaleye Management Inc
    350.00K1.24%
  • Summit Financial LLC
    346.75K1.23%
  • Ikarian Capital, LLC
    251.44K0.89%
  • Renaissance Technologies Corp
    242.50K0.86%
  • State Street Corp
    237.29K0.84%
  • Diametric Capital, LP
    196.41K0.70%
  • American Financial Group Inc
    180.00K0.64%

Top Fund Holders

  • Wasatch Micro Cap
    1.38M4.91%
  • Wasatch Micro Cap Value
    814.35K2.89%
  • Vanguard MStar Total Stk Mkt Idx Invest
    470.43K1.67%
  • First Eagle Small Cap Opportunity I
    252.44K0.89%